Entry into Contract Testing Services for In Vitro Diagnostics (IVD) and Veterinary Specimens
First written in FY2017-Q2. 4 of 7 entries say "Advanced", first in FY2020-Q2. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「Although revenue increased in the IVD and other businesses on solid sales of Fuji Dry Chem blood chemistry testing instruments and consumables, overall business revenue declined due to lower demand for medical materials in China and the impact of yen appreciation, among other factors.」
While reaffirming solid sales of Fuji Dry Chem instruments and consumables in the IVD business, the company noted that lower demand for medical materials in China and yen appreciation affected the business overall. - FY2024-Q3Lower demand for COVID-19 testing alongside growth in instrument salesAnnual report
「In the IVD sector, although the company was affected by lower demand for COVID-19-related testing reagents, revenue was at the same level as in the corresponding period of the previous year, supported by growth in sales of Fuji Dry Chem blood chemistry testing instruments and slides.」
In the IVD business, lower demand for COVID-19-related testing reagents was offset by growth in sales of Fuji Dry Chem instruments and slides, leaving revenue at the same level as in the corresponding period of the previous year. - FY2023-Q1AdvancedAnnual report
「In the IVD sector, sales of Fuji Dry Chem blood chemistry testing instruments and slides increased significantly in both Japan and overseas, while sales of biochemical and immunoassay reagents from FUJIFILM Wako Pure Chemical Corporation also performed well, resulting in higher revenue.」
The company reported growth in domestic and overseas sales of Fuji Dry Chem products and biochemical and immunoassay reagents in the IVD business, expanding its specimen testing-related operations. - FY2022-Q2AdvancedAnnual report
「In the IVD sector, sales of Fuji Dry Chem blood chemistry testing instruments and slides, as well as biochemical reagents from FUJIFILM Wako Pure Chemical Corporation, performed well, resulting in a significant increase in revenue.」
The company reported strong sales of Fuji Dry Chem products and biochemical reagents in the IVD business, expanding its specimen testing-related operations, including animal testing. - FY2021-Q3AdvancedAnnual report
「Although the IVD sector was affected by COVID-19, sales of the Dry Chem series of blood chemistry testing systems remained solid in overseas markets, supported by increased demand for animal testing and other factors.」
For the IVD business, including contract specimen testing services for animals, the company reported increased overseas demand for animal testing and solid sales of the Dry Chem series. - FY2020-Q2AdvancedAnnual report
「In the IVD sector, sales of the Dry Chem series of blood testing systems and domestic contract testing services for animals performed well.」
Domestic contract testing performed well in the animal specimen testing services business initiated by the acquisition of Monolith. - FY2017-Q2First statedAnnual report
「In the in vitro diagnostics (IVD) field, the company acquired ㈱モノリス in August 2016 and entered the contract testing services business for animal specimens.」
Through the acquisition of Monolith Co., Ltd. in August 2016, the company newly entered the contract specimen testing services business for animals in the IVD sector.